Cyclerion Therapeutics’ zagociguat was granted FDA orphan designation as a treatment of mitochondrial disease, according to a post to the agency’s website. Reference Link
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CYCN: